Cisplatin and 5-fluorouracil in refractory breast cancer patients: A phase II study

Domenico Amoroso, Paolo Pronzato, Gianfilippo Bertelli, Pietro Gallotti, Gisella Pastorino, Maria Pia Cusimano, Marco Merlano, Pier Franco Conte, Riccardo Rosso

Research output: Contribution to journalArticlepeer-review


24 patients with a median of 3 prior chemotherapy regimens were treated in our department with cisplatin 20 mg/m2 (with pre- and posthydration) and 5-fluorouracil 200 mg/m2 i.v. on day 1-5, every three weeks. 23 patients are evaluable; one had early death. 4 patients (17%) achieved a partial response, 8 had stable disease, and 11 progressed. Toxicity observed was moderate and no renal toxicity was noted. This study therefore shows tolerable toxicity but limited usefulness of adding cisplatin to 5-fluorouracil according to this schedule in these highly pretreated patients.

Original languageEnglish
Pages (from-to)269-271
Number of pages3
JournalBreast Cancer Research and Treatment
Issue number3
Publication statusPublished - Jul 1988


  • breast cancer
  • chemotherapy
  • cisplatin/5-fluorouracil synergism
  • salvage therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Cisplatin and 5-fluorouracil in refractory breast cancer patients: A phase II study'. Together they form a unique fingerprint.

Cite this